(Bizalimogene ralaplasmid + Mavilimogene ralaplasmid) is a dna vaccine commercialized by Inovio Pharmaceuticals, with a leading Phase III program in Human Papillomavirus (HPV) Associated Cancer. According to Globaldata, it is involved in 10 clinical trials, of which 7 were completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of (Bizalimogene ralaplasmid + Mavilimogene ralaplasmid)’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for (Bizalimogene ralaplasmid + Mavilimogene ralaplasmid) is expected to reach an annual total of $112 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
(Bizalimogene ralaplasmid + Mavilimogene ralaplasmid) Overview
VGX-3100 (a fixed dose combination of Bizalimogene ralaplasmid (pGX3002) and mavilimogene ralaplasmid (pGX3001)) is under development for the treatment of HPV associated anal dysplasia, cervical intraepithelial neoplasia 2/3 (CIN2/3) and vulvar intraepithelial neoplasia (VIN). VGX-3100 is a therapeutic DNA vaccine candidate administered as intramuscular injection. It targets the E6 and E7 oncogenic proteins of Type 16 and Type 18 HPV. It is based on SynCon DNA plasmid technology, ASPIRE technology and delivered using Cellectra electroporation Delivery System.
Inovio Pharmaceuticals Overview
Inovio Pharmaceuticals (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; and INO-3107 for recurrent respiratory papillomatosis (RRP). The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
The company reported revenues of (US Dollars) US$10.3 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$1.8 million in FY2021. The operating loss of the company was US$267.6 million in FY2022, compared to an operating loss of US$301.2 million in FY2021. The net loss of the company was US$279.8 million in FY2022, compared to a net loss of US$303.7 million in FY2021. The company reported revenues of US$0.1 million for the first quarter ended March 2023, a decrease of 7.8% over the previous quarter.
For a complete picture of (Bizalimogene ralaplasmid + Mavilimogene ralaplasmid)’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.